Literature DB >> 21830912

Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells.

Megha Barot1, Mitan R Gokulgandhi, Megan Haghnegahdar, Pranjali Dalvi, Ashim K Mitra.   

Abstract

PURPOSE: Multidrug resistance (MDR) represents a major obstacle to the success of antimicrobial fluoroquinolone (FQ) therapy. MDR-associated efflux protein pumps antimicrobial agents out of the corneal cells, leading to suboptimal eradication of microbes. This article examines whether long-term FQ (levofloxacin, ofloxacin, and gatifloxacin) therapy can modify the MDR phenotype (P-glycoprotein [P-gp]) on corneal epithelial cells (Statens Seruminstitut Rabbit Cornea [SIRC]).
METHODS: To study the effect of FQ, SIRC cells without any exposure to FQ (control) were compared with the cells exposed to ofloxacin, levofloxacin, and gatifloxacin at a concentration of 10 μg/mL for 3 weeks. Efflux activity of P-gp was assessed by in vitro uptake studies (fluorescent and radioactive), flow cytometry, and quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: In the presence of FQ, elevated P-gp expression was noted with uptake, flow cytometry, and qRT-PCR analyses. This study confirms that long-term exposure to antibiotics, particularly FQ, can induce overexpression of P-gp efflux transporter present on the corneal cells. P-gp overexpression is commonly noticed in anticancer drug resistance cell lines; however, for the first time, this report describes overexpression of P-gp due to FQ exposure.
CONCLUSIONS: Based on this result, it is suggested that strategies should be developed and implemented not only to overcome resistance to ocular pathogen but also to FQ-induced cellular resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830912      PMCID: PMC3235346          DOI: 10.1089/jop.2011.0076

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  29 in total

Review 1.  Real-time multiplex PCR assays.

Authors:  C T Wittwer; M G Herrmann; C N Gundry; K S Elenitoba-Johnson
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics.

Authors:  F Van Bambeke; J-M Michot; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

3.  Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.

Authors:  Deep Kwatra; Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

Review 4.  Ocular bacterial infections: current and future treatment options.

Authors:  Regis P Kowalski; Deepinder K Dhaliwal
Journal:  Expert Rev Anti Infect Ther       Date:  2005-02       Impact factor: 5.091

Review 5.  A regulatory viewpoint on transporter-based drug interactions.

Authors:  L Zhang; Y D Zhang; J M Strong; K S Reynolds; S-M Huang
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 6.  Chemotherapy resistance in breast cancer.

Authors:  M Lehnert
Journal:  Anticancer Res       Date:  1998 May-Jun       Impact factor: 2.480

7.  Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.

Authors:  Penny A Asbell; Daniel F Sahm; Mary Shaw; Deborah C Draghi; Nina P Brown
Journal:  J Cataract Refract Surg       Date:  2008-05       Impact factor: 3.351

Review 8.  ABCG2: a perspective.

Authors:  Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

9.  Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.

Authors:  T Bourcier; F Thomas; V Borderie; C Chaumeil; L Laroche
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

10.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24
View more
  7 in total

Review 1.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

2.  Effects of norfloxacin on hepatic genes expression of P450 isoforms (CYP1A and CYP3A), GST and P-glycoprotein (P-gp) in Swordtail fish (Xiphophorus Helleri).

Authors:  Ximei Liang; Lan Wang; Ruikang Ou; Xiangping Nie; YuFeng Yang; Fang Wang; Kaibin Li
Journal:  Ecotoxicology       Date:  2015-04-19       Impact factor: 2.823

3.  In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2013-10-22       Impact factor: 3.467

Review 4.  Mitochondrial dysfunction in retinal diseases.

Authors:  Megha Barot; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Curr Eye Res       Date:  2011-10-06       Impact factor: 2.424

5.  Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.

Authors:  Mitan R Gokulgandhi; Megha Barot; Mahuya Bagui; Dhananjay Pal; Ashim K Mitra
Journal:  J Pharm Sci       Date:  2012-04-12       Impact factor: 3.534

Review 6.  Recent overview of ocular patents.

Authors:  Ripal J Gaudana; Mitan R Gokulgandhi; Sai H S Boddu; Ashim K Mitra
Journal:  Recent Pat Drug Deliv Formul       Date:  2012-08

7.  Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2012-10-29       Impact factor: 3.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.